Karyopharm Therapeutics | KPTI - Selling And Administration Expenses


Karyopharm Therapeutics reported $10.42M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.63B 54M Jun/2026
Abbott USD 3.6B 330M Jun/2026
Amgen USD 1.72B 134M Jun/2026
AstraZeneca USD 5.8B 735M Jun/2026
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Eli Lilly USD 3.43B 496M Jun/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
GlaxoSmithKline GBP 2.19B 75M Jun/2026
Incyte USD 351.73M 23.64M Jun/2026
J&J USD 6.25B 168M Sep/2026
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
MacroGenics USD 9.71M 1.77M Mar/2026
Merck USD 2.89B 219M Jun/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Novartis USD 3.24B 101M Jun/2026
Novartis USD 3.14B 296M Mar/2026
Pfizer USD 3.41B 496M Jun/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Takeda JPY 286.51B 5.48B Jun/2026
Tectonic Therapeutic USD 6.43M 2.99M Mar/2026
TG Therapeutics USD 62.32M 10.82M Jun/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Xencor USD 77.54M 4.59M Jun/2026